NCT04715997View on ClinicalTrials.gov

Safety and Immunogenicity Study of GX-19N, a COVID-19 Preventive DNA Vaccine in Healthy Adults

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

185

Participants

Timeline

Start Date

December 30, 2020

Primary Completion Date

April 19, 2022

Study Completion Date

April 19, 2022

Conditions
SARS-CoV-2
Interventions
DRUG

GX-19N

DNA vaccine expressing SARS-CoV-2 S-protein antigen including the Nucleocapsid protein (NP) antigen

DRUG

Placebo

Normal saline

Trial Locations (5)

16499

Ajou University Hospital, Suwon

02447

KyungHee University Medical Center, Seoul

03722

Severance Hospital, Seoul

04763

Hanyang University Hospital, Seoul

06273

Gangnam Severance Hospital, Seoul

Sponsors

Lead Sponsor

Genexine, Inc.
All Listed Sponsors
lead

Genexine, Inc.

INDUSTRY

NCT04715997 - Safety and Immunogenicity Study of GX-19N, a COVID-19 Preventive DNA Vaccine in Healthy Adults | Biotech Hunter | Biotech Hunter